Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Lilly Endowment Inc., a director of Eli Lilly & Co. (LLY), reported open-market sales of a total of 37,148 shares of common stock on 11/20/2025. The sales were executed in multiple tranches at weighted average prices ranging from $1,050.364 to $1,055.391 per share, with underlying trade prices spanning from $1,050.00 to $1,055.59, as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owns 92,607,304 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly and Company (LLY), reported multiple sales of Eli Lilly common stock on 11/19/2025. The transactions were open-market sales at weighted average prices between about $1,050 and $1,055 per share, executed in several blocks including 96,516 shares and 28,768 shares. After these sales, the reporting person beneficially owned 92,644,452 shares of Eli Lilly common stock, held directly. The prices disclosed are weighted averages for trades within narrow price ranges, and the reporting person notes that detailed trade information is available upon request.
Eli Lilly & Co. reported insider selling by a director on Form 4. On 11/18/2025, the reporting person executed a series of open-market sales of Eli Lilly common stock, coded "S" for sale. Across ten tranches, the director sold a total of 60,213 shares at weighted average prices ranging from about $1,030 to $1,040 per share, with each tranche reported alongside a specific weighted average price and price range.
Following these transactions, the reporting person directly beneficially owned 92,811,978 shares of Eli Lilly common stock. The filing notes that detailed breakouts of the individual trade prices within each weighted range are available upon request. The form is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
Lilly Endowment Inc. has filed a Form 144 indicating a planned sale of 310,000 shares of Eli Lilly and Company common stock through J.P. Morgan Securities LLC, with an aggregate market value of 319,315,500. The filing notes that Eli Lilly had 945,383,757 shares outstanding at the time of the notice and lists 11/19/2025 as the approximate sale date on the NYSE or NASDAQ.
The securities to be sold trace back to common stock originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, in a transaction involving 38,400,000 shares. The notice also details a series of recent block sales of Eli Lilly common stock by Lilly Endowment Inc., including 351,015 shares sold on 10/01/2025 for 284,653,451.48 and 305,000 shares sold on 11/12/2025 for 308,411,211.50.
By signing, the seller represents that it is not aware of undisclosed material adverse information about Eli Lilly’s current or prospective operations.
Eli Lilly and Company director Kimberly H. Johnson reported buying 215.327 shares of Eli Lilly common stock on 11/17/2025. The Form 4 shows the shares were acquired at a price of $1,021.7 per share. After this transaction, she beneficially owns a total of 3,264.731 shares of Eli Lilly common stock directly.
Eli Lilly and Company director Gabrielle Sulzberger reported acquiring additional Eli Lilly (LLY) equity on Form 4. On 11/17/2025, she acquired 4.853 shares of common stock that, at her election, were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after she leaves the board. On the same date, she also acquired 215.327 shares of common stock. Following these transactions, she reported beneficial ownership of 2,948.32 shares of common stock in direct ownership form.
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Eli Lilly and Company director Juan R. Luciano reported acquiring a total of 229.845 shares of Lilly common stock on 11/17/2025. One transaction covered 14.518 shares that he elected to receive as stock units under the Lilly Directors' Deferral Plan instead of cash compensation, to be settled in shares after his separation from service. A second acquisition of 215.327 shares was also reported at a price of $1,021.7 per share. Following these transactions, Luciano directly beneficially owns 16,704.141 shares of Eli Lilly common stock.
Eli Lilly & Co director William G. Kaelin, Jr. reported an acquisition of company stock on a Form 4. On 11/17/2025, he acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. After this transaction, he beneficially owned a total of 21,836.814 Eli Lilly shares, held in direct ownership.
Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.